# NCT04419649 (NCT04419649)

> A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

No report yet. It can be ordered.

- Drugs tested: elritercept (KER-050)
- Indication: anemia in very-low/low/intermediate-risk myelodysplastic syndromes

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04419649
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Takeda
- Conditions: Myelodysplastic Syndromes; Cytopenia
- Interventions: Elritercept
- Enrollment: 210
- Primary outcome: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

## Indexed commentary on NCT04419649 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04419649